Medtronic PLC vs Nano Dimension Ltd - ADR — how do they compare? Medtronic PLC trades at $88.48 (market cap $112.24B), while Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M). The key difference: Medtronic PLC is far larger — about 341.7× Nano Dimension Ltd - ADR's market cap, and Medtronic PLC pays a 3.28% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| MDT | NNDM | |
|---|---|---|
Market Cap | $112.24B | $328.52M |
Volume | 105,663,236 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $105.35 | $2.14 |
52-Week Low | $73.75 | $1.21 |
Typical Hold Time | 63 Days | 43 Days |
Enterprise Value | $131.58B | -$76.33M |
Dividend Yield | 3.28% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong analyst support (60.8% buy ratings) and a $97.80 consensus price target suggesting 11.5% upside. The stock shows consistent earnings beats in recent quarters and maintains a 49-year dividend growth streak. However, technical indicators signal bearish momentum with resistance near $89-90. Revenue growth accelerated to $33.54B in 2025 with net margins improving to 13.93%, though debt levels have risen to 31.1% of assets.
MDT presents a compelling value opportunity with attractive dividend yield and earnings momentum, but faces near-term technical headwinds and increasing leverage. The upcoming Q3 earnings report and MiniMed separation will be critical catalysts. Investors should weigh the strong fundamental recovery against bearish technical signals and monitor debt management closely.
Nano Dimension (NNDM) trades at $1.55 with no recent price movement, reflecting a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but continues to report significant net losses, with a -135.18% net income margin. Recent strategic actions include cost-saving initiatives and leadership changes, with the sale of MarkForged expected to close in late 2026. Cash flow remains volatile, with 2025 showing a net cash outflow of $112M.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and asset sales provide some stability. Investment opportunities exist if cost reductions translate to profitability, but risks include ongoing operational losses and competitive pressures in the industrial sector. The stock's low valuation multiples may attract value investors, but sustained profitability is needed for long-term upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →